First reported 14 hours ago -
Updated 14 hours ago -
In Europe, two Bay Area pharmaceutical companies will go head-to-head over new drugs that both treat a rare blood cancer, chronic lymphocytic leukemia
, in patients whose disease has returned. Last week, Gilead Sciences of Foster City won federal approval ...
[Published Tech Chronicles - 14 hours ago]